Oxford, UK – 4 November 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, is pleased to announce the following business update.
The Group continues to make good progress in line with its strategy across the business model, leveraging its extensive patent estate and know-how (intellectual property or “IP”) and its expertise and capabilities in the field of lentiviral vectors.
Recent developments across the three key components of the Group’s business model are summarised below. The Group has recently introduced a numbering system for product development candidates (Central nervous system products will be numbered OXB-1XX, ophthalmology products OXB-2XX, and oncology candidates OXB-3XX).
Strong progress with wholly-owned product pipeline
Process development and manufacturing via OXB Solutions
Industry leading IP
John Dawson, Chief Executive Officer of Oxford BioMedica, commented:
“I am pleased with the progress we are making in line with our strategy. The expansion of our two manufacturing sites and the laboratories at Windrush Court is progressing well and we are looking forward soon to the approval of the new Yarnton site for GMP manufacture. We are also working hard on preparing OXB-102 and OXB-202 for their next clinical studies, which we are planning to initiate in 2016, and identifying the development path for OXB-201.
The Group continues to be recognised for its IP and expertise and continues to have strong commercial relationships with Sanofi, Novartis and GSK. I was pleased that GSK have recently re-emphasised the value of our LentiVector® platform by exercising their options to take a licence for two rare orphan disease indications. Our revenue and other income is now beginning to grow in line with our expectations with July to October being well ahead of the first four months of the year.”
- Ends -
Notes to editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications – Media Enquiries:
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
Tel: +44 (0)20 3709 5700
Peel Hunt (Joint Corporate Brokers):
James Steel/Christopher Golden
Tel: +44 (0)20 7418 8900
WG Partners (Joint Corporate Brokers):
David Wilson/Claes Spang
Tel: +44 (0)20 3705 9321